Acelyrin (SLRN) News Today $3.15 -0.07 (-2.17%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Hold Rating Maintained for ACELYRIN, INC. Amidst Izokibep Study Setback and Revised Sales ProjectionsDecember 19 at 1:42 PM | markets.businessinsider.comFmr LLC Sells 4,596,424 Shares of Acelyrin, Inc. (NASDAQ:SLRN)Fmr LLC lowered its holdings in shares of Acelyrin, Inc. (NASDAQ:SLRN - Free Report) by 97.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 117,748 shares of the company's stock after sellingDecember 19 at 3:08 AM | marketbeat.comCharles Schwab Investment Management Inc. Acquires 273,604 Shares of Acelyrin, Inc. (NASDAQ:SLRN)Charles Schwab Investment Management Inc. grew its holdings in Acelyrin, Inc. (NASDAQ:SLRN - Free Report) by 81.4% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 609,678 shares of the company's stock after purchaDecember 15, 2024 | marketbeat.comWells Fargo & Company Has Lowered Expectations for Acelyrin (NASDAQ:SLRN) Stock PriceDecember 14, 2024 | americanbankingnews.comAcelyrin's (SLRN) "Neutral" Rating Reiterated at HC WainwrightDecember 13, 2024 | americanbankingnews.comAcelyrin Finance Chief Gil Labrucherie to ExitDecember 12, 2024 | marketwatch.comAcelyrin Shares Fall After Halting Development of Eye Disease TreatmentDecember 11, 2024 | marketwatch.comAcelyrin announces izokibep trial did not meet primary endpointDecember 11, 2024 | markets.businessinsider.comAcelyrin (NASDAQ:SLRN) Stock Quotes, Forecast and News SummaryDecember 11, 2024 | benzinga.comAcelyrin (NASDAQ:SLRN) Receives "Neutral" Rating from HC WainwrightHC Wainwright reaffirmed a "neutral" rating and issued a $8.00 price objective on shares of Acelyrin in a research note on Wednesday.December 11, 2024 | marketbeat.comPoint72 Asset Management L.P. Has $1.23 Million Stock Holdings in Acelyrin, Inc. (NASDAQ:SLRN)Point72 Asset Management L.P. lifted its position in Acelyrin, Inc. (NASDAQ:SLRN - Free Report) by 566.7% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 250,300 shares of the company's stoDecember 11, 2024 | marketbeat.comACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of UveitisDecember 10, 2024 | globenewswire.comAcelyrin: Abandoned Programs Do Not Give ConfidenceDecember 9, 2024 | seekingalpha.comPolar Asset Management Partners Inc. Trims Stock Position in Acelyrin, Inc. (NASDAQ:SLRN)Polar Asset Management Partners Inc. decreased its stake in shares of Acelyrin, Inc. (NASDAQ:SLRN - Free Report) by 67.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 71,700 shares of the company's stockDecember 7, 2024 | marketbeat.comJacobs Levy Equity Management Inc. Sells 153,465 Shares of Acelyrin, Inc. (NASDAQ:SLRN)Jacobs Levy Equity Management Inc. trimmed its holdings in Acelyrin, Inc. (NASDAQ:SLRN - Free Report) by 10.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,326,391 shares of the company's stock afteDecember 6, 2024 | marketbeat.com364,000 Shares in Acelyrin, Inc. (NASDAQ:SLRN) Acquired by Acuta Capital Partners LLCAcuta Capital Partners LLC purchased a new stake in Acelyrin, Inc. (NASDAQ:SLRN - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 364,000 shares of the company's stock, valued at approximatelNovember 28, 2024 | marketbeat.comAcelyrin, Inc. (NASDAQ:SLRN) Receives Consensus Rating of "Moderate Buy" from AnalystsAcelyrin, Inc. (NASDAQ:SLRN - Get Free Report) has received a consensus rating of "Moderate Buy" from the six research firms that are covering the company, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating on the company.November 22, 2024 | marketbeat.comUCB gets FDA approval for Bimzelx for hidradenitis suppurativaNovember 20, 2024 | msn.comSHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Acelyrin, Inc. (SLRN) and Encourages Long-Term SLRN Investors to Contact the FirmNovember 19, 2024 | markets.businessinsider.comFY2024 EPS Estimates for Acelyrin Increased by HC WainwrightAcelyrin, Inc. (NASDAQ:SLRN - Free Report) - Research analysts at HC Wainwright raised their FY2024 EPS estimates for Acelyrin in a report released on Thursday, November 14th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings per share of ($2.43) for the year, up froNovember 18, 2024 | marketbeat.comVikram Purohit’s Hold Rating on ACELYRIN, INC.: Awaiting Key Data and Trial Progress for Future Stock MovementNovember 15, 2024 | markets.businessinsider.comStrategic Shifts and Promising Developments Drive ACELYRIN’s Potential Share DoublingNovember 14, 2024 | markets.businessinsider.comAcelyrin’s Phase 3 Trial Progress and Uncertainties Lead to Hold RatingNovember 14, 2024 | markets.businessinsider.comACELYRIN, INC. Receives Buy Rating from Tyler Van Buren Due to Clinical Progress and Strategic AdvancementsNovember 14, 2024 | markets.businessinsider.comAcelyrin, Inc. (SLRN) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | seekingalpha.comACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent HighlightsNovember 13, 2024 | globenewswire.comEarnings Preview: AcelyrinNovember 13, 2024 | benzinga.comAcelyrin (SLRN) Scheduled to Post Earnings on WednesdayAcelyrin (NASDAQ:SLRN) will be releasing earnings after the market closes on Wednesday, November 13, Zacks reports.November 7, 2024 | marketbeat.comACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024November 6, 2024 | globenewswire.comAcelyrin, Inc. (NASDAQ:SLRN) Given Consensus Rating of "Moderate Buy" by AnalystsShares of Acelyrin, Inc. (NASDAQ:SLRN - Get Free Report) have received an average recommendation of "Moderate Buy" from the six brokerages that are presently covering the company, MarketBeat.com reports. Three analysts have rated the stock with a hold rating and three have given a buy rating to thOctober 28, 2024 | marketbeat.comAcelyrin, Inc. (NASDAQ:SLRN) Short Interest Down 19.2% in OctoberAcelyrin, Inc. (NASDAQ:SLRN - Get Free Report) was the target of a significant decrease in short interest during the month of October. As of October 15th, there was short interest totalling 5,160,000 shares, a decrease of 19.2% from the September 30th total of 6,390,000 shares. Based on an average trading volume of 1,010,000 shares, the days-to-cover ratio is presently 5.1 days. Approximately 8.0% of the shares of the stock are sold short.October 27, 2024 | marketbeat.comAcelyrin (NASDAQ:SLRN) Stock Price Down 6.9% - Here's What HappenedAcelyrin (NASDAQ:SLRN) Stock Price Down 6.9% - What's Next?October 18, 2024 | marketbeat.comAcelyrin (NASDAQ:SLRN) Trading Up 4.8% on Analyst UpgradeAcelyrin (NASDAQ:SLRN) Stock Price Up 4.8% After Analyst UpgradeOctober 17, 2024 | marketbeat.comACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye DiseaseOctober 16, 2024 | markets.businessinsider.comWells Fargo & Company Boosts Acelyrin (NASDAQ:SLRN) Price Target to $15.00Wells Fargo & Company lifted their target price on Acelyrin from $13.00 to $15.00 and gave the company an "overweight" rating in a research note on Wednesday.October 16, 2024 | marketbeat.comAcelyrin (NASDAQ:SLRN) Stock Price Down 2.4% - What's Next?Acelyrin (NASDAQ:SLRN) Stock Price Down 2.4% - Time to Sell?October 11, 2024 | marketbeat.comAcelyrin (NASDAQ:SLRN) Shares Up 5.9% - Time to Buy?Acelyrin (NASDAQ:SLRN) Trading 5.9% Higher - Here's What HappenedOctober 10, 2024 | marketbeat.comAcelyrin, Inc. (NASDAQ:SLRN) Shares Sold by Point72 Asset Management L.P.Point72 Asset Management L.P. lessened its stake in Acelyrin, Inc. (NASDAQ:SLRN - Free Report) by 83.2% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 37,542 shares of the company's stock after selling 185,October 6, 2024 | marketbeat.comMillennium Management LLC Boosts Stock Holdings in Acelyrin, Inc. (NASDAQ:SLRN)Millennium Management LLC grew its stake in shares of Acelyrin, Inc. (NASDAQ:SLRN - Free Report) by 15.7% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 4,642,056 shares of the company's stock after buying an additional 628,528October 5, 2024 | marketbeat.comRenaissance Technologies LLC Raises Position in Acelyrin, Inc. (NASDAQ:SLRN)Renaissance Technologies LLC lifted its stake in Acelyrin, Inc. (NASDAQ:SLRN - Free Report) by 218.0% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 397,618 shares of the company's stock after purchasing aOctober 4, 2024 | marketbeat.com160,167 Shares in Acelyrin, Inc. (NASDAQ:SLRN) Bought by Susquehanna Fundamental Investments LLCSusquehanna Fundamental Investments LLC bought a new position in shares of Acelyrin, Inc. (NASDAQ:SLRN - Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 160,167 shares of the company's stock, valued at apOctober 3, 2024 | marketbeat.comAcelyrin, Inc. (NASDAQ:SLRN) Given Average Rating of "Moderate Buy" by AnalystsAcelyrin, Inc. (NASDAQ:SLRN - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the six research firms that are covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating onOctober 3, 2024 | marketbeat.comAlmitas Capital LLC Buys New Position in Acelyrin, Inc. (NASDAQ:SLRN)Almitas Capital LLC bought a new stake in shares of Acelyrin, Inc. (NASDAQ:SLRN - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 376,116 shares of the company's stock, valued at approximatelySeptember 29, 2024 | marketbeat.comShort Interest in Acelyrin, Inc. (NASDAQ:SLRN) Drops By 15.4%Acelyrin, Inc. (NASDAQ:SLRN - Get Free Report) saw a significant drop in short interest in the month of September. As of September 15th, there was short interest totalling 6,090,000 shares, a drop of 15.4% from the August 31st total of 7,200,000 shares. Approximately 9.5% of the shares of the company are sold short. Based on an average daily volume of 1,190,000 shares, the days-to-cover ratio is presently 5.1 days.September 28, 2024 | marketbeat.comAcelyrin (NASDAQ:SLRN) Shares Down 5.4% Acelyrin (NASDAQ:SLRN) Trading Down 5.4%September 23, 2024 | marketbeat.comGenSight Biologics S.A. (G49N.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024September 19, 2024 | globenewswire.comAcadian Asset Management LLC Makes New Investment in Acelyrin, Inc. (NASDAQ:SLRN)Acadian Asset Management LLC bought a new position in Acelyrin, Inc. (NASDAQ:SLRN - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 134,184 shares of the company's stock, valued at approximately $590,000September 18, 2024 | marketbeat.comLos Angeles Capital Management LLC Invests $693,000 in Acelyrin, Inc. (NASDAQ:SLRN)Los Angeles Capital Management LLC acquired a new stake in Acelyrin, Inc. (NASDAQ:SLRN - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 157,093 shares of the company's stock, valued at approximately $6September 14, 2024 | marketbeat.comSignificant Acquisition by T. Rowe Price Investment Management in Acelyrin IncSeptember 12, 2024 | uk.finance.yahoo.com Get Acelyrin News Delivered to You Automatically Sign up to receive the latest news and ratings for SLRN and its competitors with MarketBeat's FREE daily newsletter. Email Address AI breakthrough about to upend industry (Ad)Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing. I urge you to watch it now. SLRN Media Mentions By Week SLRN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SLRN News Sentiment▼0.580.60▲Average Medical News Sentiment SLRN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SLRN Articles This Week▼33▲SLRN Articles Average Week Get Acelyrin News Delivered to You Automatically Sign up to receive the latest news and ratings for SLRN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PRAX News ARVN News DAWN News ARDX News SYRE News CALT News SNDX News SPRY News ANIP News RCKT News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SLRN) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acelyrin, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acelyrin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SLRN Stock Alerts